In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma.
Jeremy’s career spans roles at Genentech, Opsona, and Inflazome, which was acquired by Roche before stepping into the CEO role at Poolbeg, a public biotech taking a different approach to drug development.
In this conversation, we talk about how Poolbeg is building a more capital-efficient, data-driven model, the realities of today’s biotech market, and how companies can position themselves to succeed in a tougher funding environment.
It’s a great in-person discussion on what it really takes to build differently in biotech today.
